- Home
- VVPR vs ANL Comparison
VVPR vs ANL Comparison
Compare VVPR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | VVPR | ANL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Power Generation | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 350.9M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VVPR | ANL |
|---|---|---|
| Price | $2.35 | $8.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.3M | 459.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $0.88 |
| 52 Week High | $8.88 | $12.09 |
Technical Indicators
Market Signals| Indicator | VVPR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 52.82 |
| Support Level | $2.22 | $1.36 |
| Resistance Level | $3.11 | $12.09 |
| Average True Range (ATR) | 0.44 | 0.82 |
| MACD | 0.06 | -0.47 |
| Stochastic Oscillator | 50.47 | 36.73 |
Price Performance
Historical ComparisonAbout VVPR VivoPower International PLC
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.